| Literature DB >> 33052249 |
Zhuqing Wan1, Ping Zhang1, Longwei Lv1, Yongsheng Zhou1.
Abstract
Recently, the rapid development of biomaterials has induced great interest in the precisely targeted treatment of bone-related diseases, including bone cancers, infections, and inflammation. Realizing noninvasive therapeutic effects, as well as improving bone tissue regeneration, is essential for the success of bone‑related disease therapies. In recent years, researchers have focused on the development of stimuli-responsive strategies to treat bone-related diseases and to realize bone regeneration. Among the various external stimuli for targeted therapy, near infrared (NIR) light has attracted considerable interests due to its high tissue penetration capacity, minimal damage toward normal tissues, and easy remote control properties. The main objective of this systematic review was to reveal the current applications of NIR light-assisted phototherapy for bone-related disease treatment and bone tissue regeneration. Database collection was completed by June 1, 2020, and a total of 81 relevant studies were finally included. We outlined the various therapeutic applications of photothermal, photodynamic and photobiomodulation effects under NIR light irradiation for bone‑related disease treatment and bone regeneration, based on the retrieved literatures. In addition, the advantages and promising applications of NIR light-responsive drug delivery systems for spatiotemporal-controlled therapy were summarized. These findings have revealed that NIR light-assisted phototherapy plays an important role in bone-related disease treatment and bone tissue regeneration, with significant promise for further biomedical and clinical applications. © The author(s).Entities:
Keywords: Near infrared light; bone tissue regeneration; bone-related diseases; drug delivery systems; phototherapy
Mesh:
Year: 2020 PMID: 33052249 PMCID: PMC7546009 DOI: 10.7150/thno.49784
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
NIR light-responsive biomaterials for bone cancer phototherapy
| Phototherapies | Photoresponsive agents | Wavelength (nm) | Power density | Radiation time (min) | References | ||
|---|---|---|---|---|---|---|---|
| PTT | Nanographene oxide sheets | 808 | 1.5 W·cm-2 | 5 | Effective decrease of osteosarcoma cell viability | - | Cicuéndez M. |
| Multi-walled carbon nanotubes (MWNTs) | 808 | 1.25 W·cm-2 | 1 | Effective decrease of breast cancer cell viability to 74.3% | Significantly suppressed growth of breast cancer bone metastasis | Lin Z. | |
| Platinum nanoparticles | 808 | 3.5 W·cm-2 | 7 | Obvious G1 arrest in cancer cells | Efficient bone-targeted anticancer activity | Zhou Z. | |
| 2.5 W·cm-2 | 10 | Effective decrease in tumor cell viability | Effective inhibition of tumor growth in a bone metastasis model | Wang C. | |||
| NaxWO3 nanoparticles | 980 | 1.5 W·cm-2 | 5 | Remarkable decrease in breast cancer cell viability | Significant decrease in tumor volume | Jie S. | |
| 2D Nb2C nanosheets | 808 | 1.0 W·cm-2 | 5 | Significant photothermal tumor cell ablation and endocytosis | Highly efficient photothermal bone tumor eradication | Lin H. | |
| 1064 | |||||||
| Carbon dot/WS2 nanosheets | 1064 | 0.6 W·cm-2 | 5 | Effective decrease of human osteosarcoma cell viability | Complete eradication of osteosarcoma without reoccurrence | Geng B. | |
| PDT | Pd-bacteriopheophorbide | 650-808 | 360 J/cm | 30 | - | Complete tumor elimination in 50% | Koudinova N. V. |
| 54 J/0.6 cm | |||||||
| Black phosphorus | 650-808 | - | 15 | Inhibited metabolic activity of osteosarcoma cells | - | Raucci M.G. |
PTT: Photothermal therapy; PDT: Photodynamic therapy.
NIR light-responsive scaffolds for bone cancer phototherapy
| Photoresponsive agents | References | Scaffolds | Irradiation condition | Step 1 mechanism: | Step 2 mechanism: | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Wavelength (nm) | Power density (W·cm-2) and | Highest tissue temp. (°C) | ||||||||
| Anti-cancer | Bone tissue regeneration | (cell type, observation time) | (animal models, observation time) | |||||||
| Bismuth (Bi) | Wang L. | Bi-doped BG scaffolds | 808 | 1.5 W·cm-2, 10 min | 55 | Photothermal effect of Bi | Osteoconductivity and osteoinductivity of BG | Complete elimination at day 3 (rat osteosarcoma cells, 15 days) | NM | |
| Hydrogenated black TiO2 (H-TiO2) | Zhang W. | Hydrogenated black TiO2 coating Ti6Al4V implant | 808 | 0.4 W·cm-2, 10 min, 2 days after implantation | 52 | Photothermal effect of H-TiO2 | Osteogenesis abilities of H-TiO2 coating with hierarchical micro/nano-topographies | 86.77% tumor cell necrosis rate (Saos-2 cells, 14 days) | Enhanced cellular adhesion, spread, proliferation, and osteogenic differentiation of rBMSCs ( | |
| Fe3O4 | Zhao P. | GdPO4/Chitosan/Fe3O4 scaffolds | 808 | 4.6 W·cm-2, 3 min for 14 days | 45.4 | Photothermal effect of Fe3O4 nanoparticles | Osteogenesis abilities of as-released Gd3+ ions | Significantly reduced tumor growth (human breast cancer bone metastasis tumor cells, 14 days) | BV/TV: 61.23 ± 2.12% (calvarial-defect model of SD rats, 12 weeks) | |
| SrFe12O19 | Yang F. | Multifunctional magnetic mesoporous calcium silicate/chitosan porous scaffolds | 808 | 0.3 W·cm-2, 6 min post-implantation | 44 | (a) photothermal effect of SrFe12O19, (b) NIR triggered DOX release | Osteogenesis abilities of magnetic nanoparticles and calcium silicate | Significantly decreased tumor growth (osteosarcoma MNNG cells, 12 days) | More newborn bone formation, BV/TV: 57.32 ± 3.53% (calvarial-defect model of SD rats, 12 weeks) | |
| Lu J. | Magnetic SrFe12O19 nanoparticles modified-mesoporous bioglass /chitosan porous scaffold | 808 | 0.3 W·cm-2 , 6 min | 43 | Photothermal effect of SrFe12O19 nanoparticles | Osteoconductivity of bioglass and SrFe12O19 nanoparticles | Tumor cell necrosis rate: 84.6% (osteosarcoma MNNG cells, 12 days) | More newborn bone formation, BV/TV: 63±4% (calvarial-defect model of SD rats, 24 weeks) | ||
| Cu-TCPP | Dang W. | Cu-TCPP-TCP composite scaffolds | 808 | 0.9 W·cm-2, 10 min every day in the first week, once every two days in the second week | 55 | Photothermal effect of Cu-TCPP nanosheets | Osteogenesis abilities of constituent elements(Cu, Ca and P) | Effective ablation and restrained growth of tumor (Saos-2 cells, 18 days) | Excellent bone-forming bioactivity (femoral defect model of New Zealand white rabbits, 8 weeks) | |
| CuFeSe2 | Dang W. | CuFeSe2 nanocrystals integrated 3D printed BG scaffolds | 808 | 0.55 W·cm-2, 10 min every day in the first week, every 2 days in the second week | 52 | Photothermal effect of CuFeSe2 nanocrystals | Osteogenesis abilities of constituent elements (Cu, Fe, Se, Ca, Si, P) | Tumor cell necrosis rate: 96% (Saos-2 cells, 14 days) | Good bone-forming | |
| MoS2 | Wang H. | MoS2/PLGA coating BG scaffolds | 808 | 2 W·cm-2, 10 min at day 1, 2, 4 and 8 | NM | Photothermal effect of MoS2 nanosheets | Osteogenesis abilities of constituent elements (Mo, Si, Ca, P) | Decreased tumor size to 15% (human osteosarcoma cells, 14 days) | Excellent osteogenic ability (calvarial-defect model of SD rats, 3 months) | |
| DTC cocrystal | Xiang H. | DTC@3D printed BG scaffolds | 808 | 1.5 W cm-2, 10 min | 55 | Photothermal effect of DTC | Osteoconductivity and osteoinductivity of BG | Promoted substantial tumor suppression (Saos-2 cells, 2 weeks) | Better newborn bone formation BV/TV: 43.5 ± 2.7% (calvarial-defect model of SD rats, 8 weeks) | |
| Graphene oxide (GO) | Xu C. | Tricalcium silicate/GO bone cement | 808 | 0.66 W·cm-2,10 minutes every two days | 55 | Photothermal effect of GO | Osteogenesis abilities of constituent elements (Ca, Si) | Decreased tumor volume, progressive apoptosis, and necrosis (Saos-2 cells, 14 days) | Enhanced cellular adhesion, spread, proliferation, and osteogenic differentiation of MC3T3-E1 cells ( | |
| Ma H. | GO/TCP 3D printed scaffold | 808 | 0.42 W·cm-2 , 10 min | 50 | Osteoconductivity and osteoinductivity of TCP | Tumor cell necrosis rate: 83.28% (osteosarcoma MG-63 cell, 15 days) | Promoted bone-forming bioactivity (calvarial-defect model of New Zealand white rabbits, 8 weeks) | |||
| Carbon dots (CD) | Lu Y. | Zero-dimensional CD doped chitosan/ nanohydroxyapatite scaffold | 808 | 1.0 W·cm-2, 10 min | 51.4 | Photothermal effect of CD | Osteoconductivity and osteoinductivity of nanohydroxyapatite | Effective suppression of tumor growth (UMR-106 osteosarcoma cells, 14 days) | Enhanced osteoinductivity (gluteus maximus muscle pouch of SD rats, 4 weeks) | |
| MXene | Yang Q. | 2D mesoporous silica@Nb2C MXene-integrated 3D printed BG scaffolds | 1064 | 1.0 W·cm-2, 10 min, 1 day after implanting | 50 | (a) Photothermal effect of Nb2C MXene,(b) NIR triggered NO release | Phosphorus and calcium components degraded from BG | Complete elimination without recurrence (Saos-2 cells, 2 weeks) | Excellent osteogenic performance (calvarial-defect model of SD rats, 24 weeks) | |
| Pan S. | 2D Ti3C2 MXene integrated 3D printed BG scaffolds | 808 | 1.0 W·cm-2, 10 min, 1 day after implanting | 63 | Photothermal effect of Ti3C2 MXene | Osteoconductivity and osteoinductivity of BG | Complete elimination without recurrence (Saos-2 cells, 2 weeks) | Better newborn bone formation (calvarial-defect model of SD rats, 24 weeks) | ||
| LaB6 | Dang W. | LaB6 micro-nanoparticles/PDLLA-modified β-TCP scaffolds | 808 | 0.7 W·cm-2, 10 min every day for a week | 53 | Photothermal effect of LaB6 micro-nanoparticles | Osteoconductivity and osteoinductivity of B element and β-TCP | The inhibition of tumor growth (Saos-2 cells, 18 days) | More newborn bone formation (femoral defect model of New Zealand white rabbits, 8 weeks) | |
BG: Bioactive glass, NM: Not mentioned, rBMSCs: Rat bone mesenchymal stem cells, BV/TV: New-bone volume/tissue volume, SD rats: Sprague Dawley rats, DOX: Doxorubicin, Cu-TCPP: Copper coordinated tetrakis (4-carboxyphenyl) porphyrin, TCP: Tricalcium phosphate, PLGA: Poly(lactic-co-glycolic acid), DTC: Dibenzotetrathiafulvalene tetracyanobenzene cocrystal, NO: Nitric oxide, PDLLA: poly(D,L-lactide).
NIR light-triggered drug delivery systems for bone cancer photo-chemotherapy
| Nanocarriers structure | Photoresponsive agents | Radiation conditions | The mechanisms of phototherapeutic effects | Anticancer drugs | Encapsulation efficiency | Release efficiency | Application | References | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Wavelength (nm) | Power density (W·cm-2) | Radiation time (min) | ||||||||
| Bismuth sulfide (Bi2S3)@mesoporous silica nanoparticles (MSNs) | Bi2S3 | 808 | 1 | 10 | The outstanding photothermal conversion efficiency of Bi2S3 nanoparticles | DOX | 99.85% | Almost 30% | Osteosarcoma | Lu Y. |
| PDA coated bioactive glass nanoparticle (BGN) | PDA | 808 | 1.4 | 10 | The stable NIR light-excited photothermal effects of PDA coating | DOX | 59% | Almost 10% (50th day, pH = 5.5) | Bone cancer therapy and bone tissue regeneration | Xue Y. |
| Gold nanorods enclosed inside mesoporous silica nanoparticles | Gold nanorods | 808 | 1.2 | 10 | The outstanding photothermal conversion efficiency of gold nanorods | ZOL | 35.4%. | Almost 90% | Breast cancer bone metastasis | Sun W. |
| PDA-alendronate /SN38 nanoparticles | PDA | 808 | 3.6 | 30 | Highly efficient photothermal effects of PDA nanoparticles | SN38 | - | Over 50% | Malignant bone tumors and osteolysis | Wang Y. |
| PDA-decorated nano-hydroxyapatite chitosan hydrogel | PDA | 808 | 2 | 2 | The excellent photothermal effects of PDA coating | Cisplatin | 91.49% | Sustained release: 71% (9th day) | Breast cancer bone metastasis and bone tissue regeneration | Luo S. |
| Bovine serum albumin (BSA)-iridium oxide (IrO2) nanoparticles | IrO2 | 808 | 1 | 5 | The superior photothermal conversion efficiency of IrO2 nanoparticles | DOX | 27.4 wt% | 46% (pH = 7.4), 68% (pH = 5.0) | Osteosarcoma | Gu W. |
DOX: Doxorubicin, PDA: Polydopamine, ZOL: Zoledronic acid, SN38: 7-ethyl-10-hydroxycamptothecin.
Phototherapy based on NIR light-responsive biomaterials for implant-related infections
| Reference | Surface modification | Photoresponsive agents | Antibacterial mechanism | Wavelength (nm) and, power density (W·cm-2) | ||||
|---|---|---|---|---|---|---|---|---|
| Highest temperature (radiation time) | Antibacterial rates ( | Highest temperature (position, radiation time) | Antibacterial rates (position, | |||||
| Yuan Z. | Mesoporous PDA nanoparticles (MPDA) + ICG + RGD coating | PDA | (a) accelerated bacterial death due to hyperthermia produced by photothermal conversion of MPDA, (b) ROS produced by released ICG with the assistance of heat | 808 nm, 0.75 W·cm-2
| 51.2 °C (5 min), | 99.7% ( | 51.3 °C (the femur of Sprague Dawley rats, 10 min), | 95.4% ( |
| Yuan Z, | MoS2/PDA-RGD coating | MoS2 | (a) hyperthermia produced by photothermal effect, (b) accelerating GSH oxidation induced by NIR, (c) intrinsic ROS-independent oxidative stress of MoS2 nanosheets | 808 nm, 0.5 W·cm-2
| 56.4 °C (8 min) | 92.7 % ( | 51.5 °C (rabbits' tibia near keen joint, 10 min) | 94.6% ( |
| Hong L. | Bismuth sulfide (Bi2S3) @ trisilver phosphate (Ag3PO4) coating | Bi2S3 | (a) hyperthermia produced by photothermal conversion of Bi2S3, (b) ROS produced by Bi2S3, (c) bacteriostatic properties of Ag3PO4 | 808 nm | 52.4 °C within 3 min | 0.5 W·cm-2 3 min + 0.25 W·cm-2 12 min: 99.45 % ( | 1.5 W·cm-2 + 1 W·cm-2 to maintain 50 °C (Sprague Dawley rats' tibia near the knee joint) | 94.54% ( |
| Huang B. | Red phosphorus/IR780/RGDC coating | Red phosphorus | (a) hyperthermia produced by photothermal conversion of red phosphorus, (b) ROS produced by IR780 under NIR light | 808 nm, 0.5 W·cm-2 | - | - | 50 °C within 10 min (rats' tibia near keen joint) | Only a few bacterial colonies ( |
| Tang L. | 808 nm, 0.5 W·cm-2
| 53.2 °C (250 s) | 89.3 % ( | 50 °C after 2 min of irradiation (rats' tibia near keen joint) | 96.2% ( | |||
| Zhang G. | TiO2/MoS2/PDA/RGD nanorod arrays coating | TiO2/MoS2 | (a) ROS produced by 660 nm VL and 808 nm NIR light, (b) hyperthermia produced by photothermal conversion of MoS2 doped TiO2 NAs, and (c) physical puncture of the nanorods. | Dual light sources (808 nm, 0.5 W cm-2; 660 nm, 0.5 W·cm-2) | 55 °C (10 min) | 97.8% ( | 50.2 °C (the back of Kunming mice, 10 min) | - |
| Su K. | Oxygen-deficient S-doped TiO2 coating | Ti-S-TiO2-x | (a) ROS produced by 808 nm NIR light and ultrasound, (b) hyperthermia produced by photothermal conversion of Ti-S-TiO2-x | 808 nm, 0.35 W·cm-2 | 54.9 °C (5 min) | 99.995% ( | - | 99.43% (the bilateral tibial plateaus of Wistar rats, |
PDA: Polydopamine, ICG: Indocyanine Green, RGD: Arginine-glycine-aspartic acid, ROS: Reactive oxygen species, GSH: Glutathione, RGDC: Arginine-glycine-aspartic acid-cysteine.
NIR light-responsive phototherapy systems for rheumatoid arthritis
| References | Phototherapy systems | Step 1: Phototherapy | Step 2: Osteogenesis | |||||
|---|---|---|---|---|---|---|---|---|
| Anti-inflammatory mechanisms | Wavelength, power density and radiation time | Photothermal effect | Photodynamic effect | Animal models | Phototherapy | |||
| Pan W. | BPNs/Chitosan/PRP thermos-responsive hydrogel | Photothermal and photodynamic properties of BPNs | 808 nm, 1.0 W·cm-2, 8 min | 43.19% photothermal conversion efficiency | Distinct ROS generation | Biotherapy of PRP and phosphorus-driven, calcium-extracted biomineralization | DBA1/J mouse rheumatoid arthritis model | 1.0 W·cm-2 808 nm NIR light for 8 min |
| Lu Y. | Cu7.2S4 nanoparticles | Photothermal and photodynamic properties of Cu7.2S4 NPs | 808 nm, 1.0 W·cm-2, 10 min | 55 °C in 500 µg·mL-1 Cu7.2S4 NPs solution | Singlet oxygen production and intracellular ROS generation | Osteogenic ability of Cu | CIA models (SD rats) | 1.0 W·cm-2, 808 nm NIR light for 10 min |
BPN: Black phosphorus nanosheets, PRP: Platelet-rich plasma, CIA models: Type II collagen induced rheumatoid arthritis models, UCNP: Upconversion nanoparticle, PJI models: Periprosthetic joint infection models.
NIR light-responsive release systems for bone tissue engineering
| Release systems | Photoresponsive agents | Wavelength (nm) | Power density | Osteogenic agents | Mechanisms | References |
|---|---|---|---|---|---|---|
| Photocaged UCNTs@mesoporous silica nanoparticles | Photocaged UCNTs | 980 | 1 W·cm-2 | Ca2+ | Photocaged UCNTs regulate the intracellular calcium and stem cells differentiation by NIR light | Kang H. |
| BP-SrCl2/PLGA microspheres | BP nanosheets | 808 | 1 W·cm-2 | Sr2+ | NIR light triggers a local temperature rise and destroys the PLGA shells to release Sr2+ | Wang X. e |
| Poly(ε-caprolactone) (PCL) networks | IR-26 dye | 1064 | 50 mJ | SDF-1α | NIR light triggers the shape switch of PCL networks to release SDF-1α | Tuncaboylu D. C. |
| Biomimetic anti-inflammatory nanocapsule (BANC) | Gold nanocage | 808 | 3 W·cm-2 | RvD1 | NIR triggers the release of RvD1 to induce the M2 polarization of macrophage cell | Yin C. |
| Heat-activated and dimerizer-dependent transgene expression system | Hollow gold nanoparticles | 808 | 11-17 mW·mm-2 | BMP-2 | Hyperthermia triggered by NIR laser activates the BMP-2 expression of cell constructs | Sanchez-Casanova S. |
UCNTs: Upconversion nanotransducer, BP: Black phosphorus, PLGA: Poly(lactic-co-glycolic acid), SDF: Stromal cell-derived factor, RvD1: Resolvin D1, BMP: bone morphogenetic proteins.
Current applications of NIR light-responsive nanomaterials in bone-related diseases phototherapies
| Applications | Administration of nanomaterials | Therapeutic mechanisms | Advantages | Drawbacks |
|---|---|---|---|---|
| Anticancer therapy | Direct intravenous injection | Photothermal and photodynamic properties of nanomaterials | Targeted accumulation in tumor sites, easy controllability | |
| Implanted bone scaffolds | (a) photothermal and photodynamic properties of nanomaterials; (b) osteogenic capability of bioactive scaffolds | Efficient anticancer properties as well as osteogenic capability | ||
| Drug delivery systems (intravenous injection) | (a) photothermal and photodynamic properties of nanomaterials; (b) combined chemotherapeutic of anticancer drugs | Combined photo-chemotherapeutic effects | ||
| Antibacterial therapy | Coating on the surface of bone implants | (a) photothermal and photodynamic properties of nanomaterials, (b) osteogenic capability of implants | Efficient noninvasive | |
| Anti-inflammation therapy | Intra-articular injection | (a) photothermal and photodynamic properties of nanomaterials; (b) combined chemotherapeutic of anti-inflammation drugs, (c) osteogenic capability of co-delivery systems | Efficient NIR light induced anti-inflammation capability, controlled release of anti-inflammation drugs as well as simultaneous osteogenic activity | |
| Bone regeneration | Implantation | Mild local heat to promote bone regeneration | Controllable bone regeneration for precise medicine | Difficulty in controlling a suitable temperature |
| Drug delivery systems (local injection) | Controlled release of osteogenic ions, drugs and proteins |